What is ASKP?
The American Society of Ketamine Physicians is a group of professionals dedicated to the safe clinical use of ketamine for mental health disorders and pain conditions.
ASKP is officially open for membership.
2019 ASKP Annual Meeting
Conference runs September 20th – 21st
Basics of Administration
All of the providers in our group ascribe to the same basic tenets of safety when administering Ketamine for Non-Anesthetic Indications (KNAI).
1. ASKP serves as a forum to discuss the use of therapeutic Ketamine for Non-Anesthetic Indications (KNAI). KNAI is fundamentally different than the traditional use of ketamine as an anesthetic.
2. We recognize that therapeutic ketamine is being administered by clinicians through different routes of delivery (IV, IM, IN, PO, etc.). ASKP does not endorse any particular route of delivery however we feel it is important that the combination of delivery and dose do not cross over from KNAI to moderate sedation unless the provider and clinical setting are appropriate for that treatment.
3. ASKP is not a certifying organization. Membership in ASKP and the presence of the ASKP logo on a practitioner’s website does not imply any endorsement of that practitioner’s quality of care by ASKP.
4. Patients should be screened for and have been found to have a condition that is appropriate for ketamine treatment – examples include Unipolar Major Depression, Bipolar Depression, PTSD, OCD, Fibromyalgia, CRPS and other forms of chronic pain.
5. A full history and physical including psychiatric disorders and substance abuse disorders should be completed in the patient’s chart. The patient’s medications and allergies should also be documented to reduce reasonable risk of medication interaction and side effects.
6. Given the off-label nature of ketamine use for these disorders, appropriate consent should be obtained.
7. Practitioners should have their established protocol easily available to the public. The use of “secret formulations” and “proprietary blends” runs counter to the concept of evidence-based medicine.
8. The patient’s vital signs should be monitored during administration and return to pre-administration values before discharge from the clinic. An appropriately licensed and qualified medical provider should be present during the administration as well.
9. Patients receiving ketamine therapeutically should not be allowed to drive themselves home from their appointment, or for 12 hours after their infusion.
10. We do not support the use of medically unsupervised parenterally administered ketamine.
Thank you again for your interest in joining our society. Please click below to fill out the application
*Your application is subject to approval. We reserve the right to decline your membership. Once membership is approved, and payment is accepted, memberships and payments will automatically renewed annually, unless ASKP membership staff is notified in writing.
ASKP Mailing Address:
6565 West Loop, Ste 530
Bellaire, TX 77401-3500
2017/2018 American Society of Ketamine Physicians Officers & Board Members
Questions can be addressed to: email@example.com
Steven Mandel, MD* – President
Steven Levine, MD* – Vice-President
Sandhya Prashad, MD* – Secretary
Carl J. Bonnett, MD* – Treasurer
Nykol Bailey Rice, CRNA
Jake Hollingsworth, DO* – Webmaster
Megan Oxley, MD* – Membership Chair
Cindy Van Praag, MD
Patrick Sullivan, DO
Rachel Dalthrop, MD
*Founding Board Members
The Society does not endorse any of the products, vendors, providers,documentation, or services referenced in this website. Any mention of products, vendors, providers, documentation, or services is for informational purposes only